JoshuaEricReussMD

Oncology • Washington, DC

Physician

Join to view full profile

Dr. Reuss is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Reuss' full profile

Already have an account?

Office
3800 Reservoir Rd
Washington, DC 20007
Phone+1 202-444-2223

Education & Training

University of Virginia Medical CenterResidency, Internal Medicine, 2014 - 2017
University of Rochester School of Medicine and DentistryClass of 2014

Certifications & Licensure

DC State Medical License 2020 - 2026
MD State Medical License 2017 - 2025
VA State Medical License 2014 - 2017
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Medical Oncology

Clinical Trials

Tiragolumab With Atezolizumab Plus Bevacizumab in Previously-Treated Advanced Non-squamous NSCLC Start of enrollment: 2021 Dec 21
Recruiting
Phase 2
A Study of Avutometinib (VS-6766) + Defactinib in Recurrent KRAS G12V, Other KRAS and BRAF Non-Small Cell Lung Cancer Start of enrollment: 2020 Dec 31
Completed
Phase 2
Roles: Principal Investigator, Contact
Neoadjuvant Chemo-Immunotherapy and Surgical Resection in Locally Advance Non-Small Cell Lung Cancer Start of enrollment: 2024 Sep 01
Not yet recruiting
Phase 2
Roles: Principal Investigator, Contact

Publications & Presentations

PubMed

Targetable molecular algorithm and training platform development for the treatment of non-small cell lung cancer.
Krithika Bhuvaneshwar, Chul Kim, Kaushal Parikh, Joshua E Reuss, Camelia Bencheqroun
JAMIA Open. 2024-12-01
Divergent clinical and immunologic outcomes based on STK11 co-mutation status in resectable KRAS-mutant lung cancers following neoadjuvant immune checkpoint blockade.
Samuel Rosner, Sydney Connor, Khaled Sanber, Marianna Zahurak, Tianbei Zhang
Clinical Cancer Research. 2024-11-15
Consolidation ALK Tyrosine Kinase Inhibitors Versus Durvalumab or Observation After Chemoradiation in Unresectable Stage III ALK-Positive NSCLC.
Amin H Nassar, Ritujith Jayakrishnan, Jamie Feng, Frances Shepherd, Elio Adib
Journal of Thoracic Oncology. 2024-09-10

Journal Articles

Immune-Related (IR)-Pneumonitis During the COVID-19 Pandemic: Multidisciplinary Recommendations for Diagnosis and Management
Joshua E Reuss, Karthik Suresh, David Feller-Kopman, Clare Rock, Julie R Brahmer, Journal For Immunotherapy of Cancer

Lectures

Neoadjuvant nivolumab in resectable non-small cell lung cancer: Extended follow-up and molecular markers of response.
ASCO Annual Meeting 2019 - Chicago, IL - 6/2/2019

Press Mentions

Investigational Drug Shows Promise in a Clinical Trial for Lung Cancers with ALK MutationsNovember 8th, 2024

Professional Memberships

American Society of Clinical Oncology - ASCO
Member